- Home
- RMI vs RCEL Comparison
RMI vs RCEL Comparison
Compare RMI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMI | RCEL |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.9M | 102.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMI | RCEL |
|---|---|---|
| Price | $14.59 | $4.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.17 |
| AVG Volume (30 Days) | 17.4K | ★ 233.5K |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 7.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,401,000.00 |
| Revenue This Year | N/A | $13.61 |
| Revenue Next Year | N/A | $19.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $13.05 | $3.22 |
| 52 Week High | $17.37 | $11.25 |
Technical Indicators
Market Signals| Indicator | RMI | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 73.40 |
| Support Level | $14.53 | $3.24 |
| Resistance Level | $14.73 | $3.94 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 59.99 | 87.31 |
Price Performance
Historical ComparisonAbout RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.